SAN DIEGO, Aug. 20, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cur… […]
CARLSBAD, Calif., Aug. 14, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) today announced business highlights and financial results for the fiscal year 2021 first quarter, ended June 30, 2020.
Business hig… […]
Completion of Dosing in Phase 1 Multiple Ascending Dose Study (“MAD”) of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease (“ADPKD”)FDA Orphan Designation of RGLS4326 for ADPKDAppointment of Denis Drygin, Ph.D., as Chief S… […]
SAN DIEGO, Aug. 11, 2020 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fi… […]
Successful completion of $300 million initial public offering; cash and cash equivalents of over $350 million as of June 30, 2020Strengthened leadership team with additions of Michael MacLean as Chief Financial Officer and Jae Kim, M.D., as Chief Medic… […]
– Reports First Quarter of Expected Sustainable Profitability and Maintains 2020 Guidance of $230 to $245 Million in Revenues and $0.60 to $0.75 Earnings Per Share — Two U.S. FDA Approvals and One EMA Approval Received by Partners for Products Utilizi… […]
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the second quarter ended June 30, 2020.
“Mirati is working to d… […]
SAN DIEGO, Aug. 5, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet p… […]
– Advancing Precommercial Activities in Preparation for Phexxi(TM) Commercial Launch in September 2020 — Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea on Track for Q4 2020 Initiation — Management to Host Conference Call Tu… […]
Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH; New Data from 12-Week Phase 2 Trial to be Highlighted at EASL- IND Filed for VK0214 in X-ALD; Phase 1 Trial Expected to Begin Q3 2020- Ba… […]
Revenues of $1.4 million increased 41%, revenue per accession increased 27%Conference call begins at 4:30 p.m. Eastern time today
SAN DIEGO, May 13, 2020 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular technologies desig… […]
SAN DIEGO, May 13, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the thre… […]
– DARZALEX FASPRO(TM) Utilizing ENHANZE® Technology Receives U.S. FDA Approval with Subcutaneous Administration Time of 3 – 5 Minutes and Lower Rate of Administration-related Reactions When Compared with IV DARZALEX® — Positive CHMP Opinion Recommendi… […]
SAN DIEGO, May 7, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the first quarter ended March 31, 2020.
“Despite the challenges … […]
SAN DIEGO, May 7, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the first quarter ended March 31, 2020.
“Despite the challenges … […]
SAN DIEGO, May 7, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the first quarter ended March 31, 2020.
“Despite the challenges … […]
SAN DIEGO, May 6, 2020 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results fo… […]
INGREZZA® (valbenazine) First Quarter Net Product Sales of $231 Million with Approximately 41,500 TRxONGENTYS® (opicapone) Approved by the U.S. Food and Drug Administration (FDA) as a Once-Daily Adjunctive Treatment for Patients with Parkinson’s Diseas… […]
– On-Track for Phexxi(TM) PDUFA Date: May 25, 2020 — End-of-Phase 2 Meeting with FDA Today to Review Results of the AMPREVENCE Trial — Management to Host Conference Call Wednesday, May 6, 2020 at 11:00 a.m. EDT –
SAN DIEGO, May 6, 2020 /PRNe… […]
Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]
Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]
Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]
SAN DIEGO, April 23, 2020 /PRNewswire/ –?Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020.
On February 19, 2020, Toc… […]
SAN JOSE, Calif., April 8, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today… […]
– Fourth quarter revenues reached a record $1.8 million, up 108% over the fourth quarter of 2018 and up 17% over the third quarter of 2019- Fourth quarter commercial revenues increased 94% over the fourth quarter of 2018 and increased 11% over the thir… […]
— U.S. Food and Drug Administration (FDA) Grants Conditional Approval for New Brand Name – Phexxi(TM) —- PDUFA Date of May 25, 2020 Assigned for Phexxi New Drug Application (NDA) —- End-of-Phase 2 Meeting Scheduled with FDA to Review Results of th… […]
Copyright © 2021 Biotech Networks, LLC
